Oncocyte enters $7.5M ATM with Needham, terminates prior $50M BTIG ATM

Insight Molecular Diagnostics Inc.

Enters Sales Agreement with Needham & Company for up to $7.5M of common stock at-the-market.
Terminates prior ATM agreement with BTIG, LLC dated June 11, 2021 for up to $50M.
Company may sell shares from time to time; Needham receives 3.0% commission on gross proceeds.
Net proceeds intended for working capital and general corporate purposes.
Placement shares registered under S-3 effective August 7, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.